Moderna, Inc. (MRNA)
Moderna expects 2025 revenue of $1.9B, above guidance
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) said it expects 2025 revenue of approximately $1.9 billion, about $100 million above the midpoint of its previously communicated guidance of $1.6 to $2 billion. The company also raised its 2025 GAAP operating expense outlook by $200 million to a range of $5 to $5.2 billion and projects a year-end cash balance of approximately $8.1 billion, including a $0.6 billion drawdown from a recently announced $1.5 billion term loan facility.
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below revenue levels achieved during the COVID-19 pandemic.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) on Monday reiterated its 2025 revenue guidance of $1.6 billion to $2.0 billion and outlined its pipeline milestones for 2026-28, with the company continuing to focus on Covid-19 as its near-term revenue driver. In its annual letter, Moderna highlighted that its Covid vaccines remain central to 2026, with the mNEXSPIKE vaccine representing roughly 24% of all US retail Covid vaccinations in 2025 and nearly one-third of vaccinations among adults aged 65 and older.
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna shares are down almost 28% in the year to date, trading just shy of $30 on Friday morning.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
Moderna (MRNA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRNA broke through the 50-day moving average, which suggests a short-term bullish trend.
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
